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Abstract Selegiline, the irreversible inhibitor of mono-
amine oxidase B (MAO-B), is currently used to treat
Parkinson’s disease. However, the mechanism of action of
selegiline is complex and cannot be explained solely by its
MAO-B inhibitory action. It stimulates gene expression, as
well as expression of a number of mRNAs or proteins in
nerve and glial cells. Direct neuroprotective and anti-
apoptotic actions of selegiline have previously been
observed in vitro. Previous studies showed that selegiline
can induce neuronal phenotype in cultured bone marrow
stem cells and embryonic stem cells. Embryonal carcinoma
(EC) cells are developmentaly pluripotene cells which can
be differentiated into all cell types under the appropriate
conditions. The present study was carried out to examine
the effects of selegiline on undifferentiated P19 EC cells.
The results showed that selegiline treatment had a dramatic
effect on neuronal morphology. It induced the differentia-
tion of EC cells into neuron-like cells in a concentration-
dependent manner. The peak response was in a dose of
selegiline significantly lower than required for MAO-B
inhibition. The differentiated cells were immunoreactive for
neuron-specific proteins, synaptophysin, and β-III tubulin.
Stem cell therapy has been considered as an ideal option for
the treatment of neurodegenerative diseases. Generation of
neurons from stem cells could serve as a source for
potential cell therapy. This study suggests the potential
use of combined selegiline and stem cell therapy to improve
deficits in neurodegenerative diseases.
Keywords Neuronal differentiation . Embryonic carcinoma
cells . Neuron specific markers . Synaptophysin .β-III
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Introduction
Selegiline (deprenyl) a neuroprotective pharmacological
drug (Fedchenko et al. 2008), was one of the first adjunct
therapies in clinical neurology (Ebadi et al. 2002). It has
been used to irreversibly inhibit monoamine oxidase B
(MAO-B) in Parkinson’s disease (PD) and Alzheimer’s
disease (AD). Selegiline has been demonstrated to exert
anti-apoptotic, neuroprotective effects on a number of in
vitro and in vivo models in a dose significantly lower than
required for MAO-B inhibition (Palfi et al. 2006). Other
researches have shown that the drug can induce expression
of a number of genes (Tatton 1996; Fedchenko et al.
2008). Selegiline reduces PC12 cell apoptosis by inducing
new protein synthesis (Tatton et al. 1994). Induction of
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nerve growth factor (NGF) mRNA expression in cultured
rat cortical astrocytes followed by a corresponding
increase in NGF protein content was reported by this drug
(Semkova et al. 1996). Selegiline blocks apoptosis and
regulates the expression of apoptosis-related genes (Xu et
al. 1999). This agent has a trophic effect on cultured
neurons (Iwasaki et al. 1994). Also, it can improve signs
of senility (Knoll 1983). A research in tissue culture and
animal models has shown that selegiline can reduce
neuronal apoptosis through a mechanism(s) that does not
require MAO-B inhibition (Tatton 1996). Selegiline is
efficient and a potent inducer for differentiation of bone
marrow stem cells into neuronal phenotype (Ghorbanian et
al. 2010).
Embryonal carcinoma (EC) and embryonic stem (ES)
cells are developmentally pluripotent cells. These cells
can differentiate into all cell types under the appropriate
conditions. Retinoic acid (RA) induces the pluripotent
EC and ES cells to differentiate into various lineages
(Rohwedel et al. 2000). Bain et al. showed that RA
enables differentiation of ES cells into neuron-like cells
(Bain et al. 1995). In vitro differentiation of mouse ES
cells into neuron-like cells demonstrated using nerve
growth factor (Wobus et al. 1988). Dimethylsulfoxide
(DMSO) also was reported to induce differentiation of
these cells into neurons (Dinsmore et al. 1996). Lithium
chloride has been shown to increase mRNA levels of
genes encoding synaptophysin and the 160-kDa neurofila-
ment protein (Schmidt et al. 2001). Selegiline induces
neuronal phenotype and neurotrophin gene expression in
ES cells (Esmaeili et al. 2006).
P19 cells are murine EC cells that have been used as a
model system for studying early embryonic development
and differentiation. P19 cells can be induced to differen-
tiate with RA into cell types similar to those derived
from neuroectoderm (MacPherson and McBurney 1995).
The neurons obtained in these cultures are irreversibly
postmitotic, show a typical neuronal morphology and
exhibit a number of markers characteristic of CNS neurons
such as neurofilament proteins (MacPherson et al. 1997),
synaptophysin, and the brain-specific III tubulin (Falconer
et al. 1992).
Stem cell therapy has been considered as an ideal option
for the treatment of diseases such as PD. A recent
investigation reported that ES cell therapy improves
neurologic disorders (He et al. 2003). Neuron and synapse
loss are important features of the neuropathology of PD
(Hou et al. 2010) and AD (Rutten et al. 2005; Bailey and
Lahiri 2010). Selegiline, used clinically in PD, has multiple
pharmacological effects which make it a good candidate to
treat neurotoxicity (Davidson et al. 2007).
Because selegiline induces neurotrophin gene expression
and fetal neuron differentiation, as well as neuronal
phenotype in ES and BMS cells, it may have the same
effects on EC cells. Based on these findings, we investi-
gated the effect of selegiline on in vitro differentiation of
P19 EC cells into neuron-like cells. Samples were analyzed
to determine what influence this drug may have on neuron-
specific markers and neuronal morphology.
Materials and Methods
Cell culture and viability test. The studies reported here
were carried out with the P19 line of murine EC stem cells
(McBurney 1993). Undifferentiated P19 cells were grown
in α-MEM (Gibco-BRL, Carlsbad, CA, 11900073) supple-
mented with 15% fetal bovine serum, penicillin (50 μg/ml),
and streptomycin (50 μg/ml). The cells were kept in a
humidified cell culture incubator at 37°C under 5% CO2
with close control of pH. The viability of EC cells during
the experiment was determined by the trypan blue dye
exclusion method (Freshney 1994). The cells were removed
from the dishes using trypsin/EDTA, and the isolated cells
were centrifuged at 1,000 rpm for 10 min. The pellet was
resuspended in PBS and stained with trypan blue (0.4%) dye.
After 5 min at room temperature, viable and dead (blue
stained) cells were counted using a hemocytometer under a
microscope using a ×40 magnification. The percentage of the
viable cells (PVC) was estimated, plotted against the dose
used in the study, and subjected to linear regression analysis.
Different concentrations of selegiline (was provided as a gift
from Zahravi Pharmaceutical Company, Tabriz, Iran) were
used for viability assay (10-6–10-11 M). The assay was
repeated at least five times.
Dose–response evaluation. We determined the dose–re-
sponse relationship for percentage of neuronal induction
(PNI). The optimal doses of selegiline that induced
neuronal differentiation were 10−8–10−10 M. The peak
response for neuronal induction was at 10−8 M, which
was used for further investigation. Cresyl violet was used to
count the differentiated neurons.
Cresyl violet staining. Adherent cells were fixed in 70%
ethanol for 10 min at room temperature and dehydrated as
described for immunostaining (in 95% ethanol/5% acetic acid
for 20 min at −20°C), then washed twice in PBS for 10 min.
Cells incubated for 3–10 min in staining solution: 0.25%
cresyl violet, 0.8% glacial acetic acid, 0.6 mM sodium acetate
(Fraichard et al. 1995). Cells were washed in PBS, four times
10 min each, and then mounted for examination. PNI was
determined from direct counts of stained cells. Five
microscopic fields under ×40 magnification were randomly
picked to count neuron-like (cresyl violet-stained) cells, and
mean values were calculated for each group.
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Differentiation induction protocol. Undifferentiated EC
cells were dissociated into single-cell suspensions and then
cultured in hanging drops to induce embryoid body (EB)
formation at an initial cell density of 500 cells per 20-μl
drop. EBs were cultured on 0.1% gelatin-coated petri dishes
containing cover slip in α-MEM supplemented with 3%
FBS. Neuronal differentiation induction of EBs was
achieved by RA (5×10−7 M) as a positive control
(control+), and no inducer as a negative one (control−). In
the treatment group, 10−8 M concentration of selegiline was
used to induce EBs differentiation to neuronal lineage.
Immunoflourescence. The following primary antibodies
were used in this study: mouse anti-synaptophysin mono-
clonal antibody (Abcam, San Francisco, CA, ab8049) to
identify the mature neurons and mouse anti β-III tubulin
monoclonal antibody (Abcam, ab7751). FITC-conjugated
anti-mouse IgG (Sigma, St. Louis, MO, F9137) was used as
a secondary antibody.
For immunoflourescence, cells were cultured in 12-
well plates. The cells were grown on a cover slip, fixed
in 4% paraformaldehyde, rinsed three times with PBS,
permeabilized with 0.3% Triton X-100 in PBS for
30 min at 37°C. Following three washes with PBS, the
cells were incubated with 10% normal goat serum
(Sigma, G9023) in PBS for 30 min, to block nonspecific
binding. Afterwards, the cells were incubated with the
relevant primary antibody for 60 min, followed by
incubation with the secondary antibody for 30 min. All
antibodies were used at the same dilutions (1:1,000).
Cover slips were mounted with 70% glycerol in PBS.
Several controls for immunostaining were used, and the
primary antibody was omitted.
Formalin-fixed paraffin-embedded sections of chicken
embryo with neural tube were used as positive control.
Embryos were fixed in formalin, dehydrated through an
ethanol series into xylenes and then embedded in paraffin
and parasagittally sectioned at 5 μm. Slides were
dewaxed in xylenes, rehydrated through decreasing
concentrations of ethanol, and washed in PBS. All slides
were treated with 2% sodium borohydride (Sigma,
S9125), for 30 min followed by incubation in 0.1 M
glycine to quench endogenous formalin-related fluores-
cence (Jagla et al. 2000). Antigen retrieval was done
enzymatically. Details of all antibodies used are in the
previous section.
Statistical analysis. The statistical analysis of the data was
done using SPSS. The data were tested for normality using
the S-K test. Analysis of variance followed by Duncan test
was used to compare the data among the groups of PNI and
PVC. The data were presented as means and standard
deviation of the means.
Results
Viability assay. Linear regression analysis was done for
the cell viability data in which the logarithm of dose
against PVC was used. Table 1 shows PVC at 10−10 M,
and higher concentrations of selegiline were significantly
lower than that in the untreated group (control−). There
was a significant difference between the control− and
10−6–10−10 M, and no significant difference between the
control− and 10−11 M. PVC at 10−6–10−8 M was
significantly lower than that in the RA-treated group
(control+), while at 10−11 M was significantly higher. The
table shows no significant difference between control+
and 10−9 and 10−10 M. Significant differences existed
between all different concentrations of selegiline with
each other.
Neuronal differentiation of EC cells by selegiline. The
statistical differences among the groups used in the study
showed that PNI was significant between 10−8–10−10 M
concentrations of selegiline and both controls (RA and
control−). Table 1 show that the PNI at 10−10 M and higher
concentrations of selegiline were significantly more than
the control− and less than control+. Significant differences
existed between 10−8, 10−9, and 10−10 M. The peak
response was at 10−8 M, which was used for further
investigation to study the EC cell-derived neuron-like cells.
Cresyl violet staining. Figure 1 shows the morphology of
the differentiated EC cells using cresyl violet. This stain
is commonly used for identifying the basic neuronal
structure. Selegiline-treated EBs were plated in gelatin-
Table 1. The viability assay and neuronal induction of the P19 EC
cell line to different concentrations of selegiline
Groups Concentration (M) PVC mean±SD PNI mean±SD
Sel 10−6 29. 8±3.5*,*** ND
Sel 10−7 39.2±4.5*,*** ND
Sel 10−8 56. 5±2.6*,*** 89±4.4**,****
Sel 10−9 65.1±3.2* 82±5.3**,****
Sel 10−10 69.7±2.8* 71.3±5.9**,****
Sel 10−11 74.3±4.6*** ND
RA 5×10−7 66.9±3.8 94.3±2.2
Cont.− 0 76.5±3.3 11.4±2.3
The data present the means and the standard deviation of the means of
the PVC and the PNI in different concentrations used in the study.
Selegiline induced the differentiation of P19 EC cells at a higher mean
than that of the untreated group (control− ). RA as control+
Sel selegiline, RA retinoic acid, ND not done, Cont.− control−
*P<0.05, vs. Cont.− ; **P<0.05, vs. Cont.− ; ***P<0.05, vs. RA;
****P<0.05, vs. RA
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coated dishes, and then allowed to attach and form
outgrowth cultures. Proliferative cells spread around it in
a cell monolayer structure. Selegiline treatment had a
dramatic effect on neuronal morphology (Fig. 1A). Cresyl
violet staining was used for the detection of Nissl body in
the cytoplasm of neurons (Fig. 1C). Neuron-like cells
formed a cellular network on top of the monolayer
(Fig. 1B). Figure 1D shows P19-derived neurons induced
to differentiate with 5×10−7 M retinoic acid, as positive
control. Figure 1E shows P19 cells treated without drug,
as negative control.
Detection of neuron-specific proteins. To characterize post-
mitotic neurons, expression of neuron specific proteins,
β-III tubulin, and synaptophysin were tested using
specific antibodies. Immunoflourescence evaluation of
the differentiated P19 cells showed that these cells were
immunoreactive to synaptophysin and β-III tubulin after
selegiline treatment (Fig. 2C, D). Neurons positive for β-
III tubulin or synaptophysin were detected either as
individual cells or in small aggregates. Chicken embryo
neural tube was examined for a positive control condition
(Fig. 2A, B).
Discussion
In this study, we investigated the induction of neural
differentiation of P19 EC cells by a neuroprotective
pharmacological drug, selegiline. About 2 wk after induc-
tion by selegiline, subsets of the cells showed morphology
of neurons. Our results documented that the neural
differentiation of mouse EC P19 cells, was further
accelerated by the addition of selegiline into media in a
dose-dependent manner. Morphological and cell biological
changes were followed during selegiline induced neural
differentiation. The neurons obtained in these cultures
showed a typical neuronal morphology and exhibited a
number of markers characteristic of neurons such as
synaptophysin and β-III tubulin.
The cells of many embryonal carcinoma lines differen-
tiate if cultured at high density (McBurney 1976) or as
aggregates (Martin and Evans 1975). However, differenti-
ation of P19 cells can be induced if aggregates are exposed
to nontoxic concentrations of a number of drugs. The drugs
most effective in inducing differentiation of P19 cells are
RA (Jones-Villeneuve et al. 1982) and DMSO (McBurney
and Rogers 1982). Finley et al. have shown that within 2–
Figure 1. Photomicrographs show P19 EC cells differentiated into
neurons, using selegiline as inducer. (A) After about 2 wk, cells showed
the characteristic morphology of neuronal cells (soma and neurites).
Neurons have formed aggregates with areas of lower density of neuronal
cell bodies in between. The aggregates are interconnected by fine
processes. Cresyl violet was used to stain the differentiated neurons. (B)
Neuronal-like cells formed a cellular network on top of the monolayer
(arrow). The arrowheads indicate the neuronal extension. (C) Neuron-
like cells show Nissl bodies in their cytoplasm (arrow). The asterisk
indicates a non-neuronal cell with distinctive nucleus and nucleolus
(arrowhead). (D) P19-derived neurons induced to differentiate with 5×
10−7 M retinoic acid, as positive control. (E) P19 cells treated without
drug, as negative control. (A, B, E) ×10, (C) ×100, (D) ×40.
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3 wk after induction by RA, pluripotent EC cells, P19, and
totipotent ES cells pass from a nearly (P19) or totally (ES)
uncommitted phenotype to one that strongly resembles
mature neurons (Finley et al. 1996). In vitro differentiation
of mouse ES cells into neuron-like cells was reported using
nerve growth factor (Wobus et al. 1988). This is the first
report to our knowledge about the induction of neuronal
differentiation of EC cells by selegiline. In order to be
driven to neural lineage, EC cells cultured under non-
adherent conditions that support the formation of EBs.
Resulting EBs were plated on standard tissue culture dishes
and then exposed to selegiline. The cultures continued
without selegiline for more than 1 mo.
Direct neuroprotective and anti-apoptotic actions of
selegiline have previously been observed in vitro and in
vivo, in a dose significantly lower than required for
MAO-B inhibition. Selegiline reduces the secretion of
neurotoxin products in a concentration-dependent man-
ner (Klegeris and McGeer 2000). We used cell viability
and dose response assay to decide the range of neuronal
induction concentration (10−6–10−11 M). The best selegi-
line concentration to neural cell induction of P19 cells was
10−8 M. The cells generated an extensive network of
processes during the 2–3 wk after induction. In our earlier
investigations using selegiline, this drug could induce
neuronal morphology as well as neurotrophin gene
expression in ES cells at the concentration of 10−8 M
(Esmaeili et al. 2006). Selegiline has been shown to
increase neuronal survival and to alter protein synthesis
and gene expression in astrocytes or PC12 cells indepen-
dently of MAO-B inhibition (Tatton et al. 1994). Tatton et
al. reported that selegiline reduced both cell death and
internucleosomal DNA degradation in a concentration-
dependent manner and was effective at concentrations too
low to inhibit MAO (<10−9 M) (Tatton et al. 1994). At
concentrations as low as 0.0001 and 0.001 μM, selegiline
significantly increased the number of surviving cells
under serum-free and hypoxic conditions, respectively
(Xu et al. 1999). Selegiline (10 pM–1 nM) induced NGF
mRNA expression in cultured rat cortical astrocytes
followed by a corresponding increase in NGF protein
content (Semkova et al. 1996). It reduces neuronal death
at concentrations too small to cause MAO-B inhibition
(Tatton 1996).
Embryonic stem (ES) and embryonal carcinoma (EC)
cells may provide information that is pertinent one to the
other. Both of these cell types share the general properties
of pluripotent stem cells in that they exhibit unlimited self-
renewal and can give rise to derivatives of all three
embryonic germ layers. They can be considered as
complementary tools to study the developmental mecha-
nisms. In 1984, Andrews et al. reported that compared to
human ES cells, human EC cells seem to have less
differentiation capacity in vivo and are usually aneuploid.
Figure 2. Fluorescence micro-
graphs illustrating the expres-
sion of neuronal markers.
Chicken embryo neural tube
was examined for a positive
control condition: (A) arrows
show β-III tubulin-positive
cells in the neural tube, (B)
arrows show synaptophysin-
positive cells in the neural tube,
asterisks indicate somites. P19
cells treated with selegiline
show immunoreactivity for β-
III tubulin, a classic marker for
differentiating neurons (C), and
synaptophysin, a reliable mark-
er of nerve terminal differenti-
ation (D). Synaptophysin
concentrated in a brightly fluo-
rescent spot (arrow). (A, B) ×4,
(C) ×40, (D) ×100.
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Therefore, because of their karyotype, EC cells are not
suitable for clinical applications (Andrews et al. 1984).
However, Passier et al. reported that after differentiation,
EC cells are no longer malignant; they therefore became not
only a useful model for the study of development, but were
also of interest to oncologists testing differentiation–
induction as therapy for teratocarcinoma (Passier and
Mummery 2003).
The P19 mouse EC line is an excellent widely used
model to analyze regulation of neuronal development and
differentiation. P19 cells have a normal male karyotype
(McBurney and Rogers 1982). They are widely available,
easily cultured without feeders, and do not usually require
special growth conditions. In addition, the neurons derived
from this cell line have been successfully used in
transplantation studies in several mouse models (Astigiano
et al. 2005). Undifferentiated P19 cells are amenable to
genetic manipulations such as transfection and establish-
ment of stable clonal cell lines expressing introduced genes
(Bain et al. 1994).
Here, a simple and efficient strategy is proposed to serve
as a basis for neurodifferentiation studies in vitro. To create
the basis for further experimentation, we first tested
whether the cells of the mouse EC cell line P19 also
acquire a neural phenotype after treatment by selegiline.
The differentiated cells were then used in the transplanta-
tion studies in our experiments (data not shown).
In accord with the earlier work of others, we showed
that selegiline could induce neuronal markers, β-III
tubulin and synaptophysin in differentiated EC cells. It
has been previously demonstrated that neurons derived
from ES cells by selegeline induction, were immunore-
active for synaptophysin (Esmaeili et al. 2006). In this
study, the formation of synapses between P19-derived
neurons in mature cultures has been documented by
immunoreactivity for synaptophysin. One of the most
extensively studied synaptic proteins is synaptophysin
(Masliah and Terry 1993). Synaptophysin is a reliable
marker of nerve terminal differentiation (Sortwell et al.
1998). It has been previously demonstrated that P19-
derived neurons form synapses in vitro and are immuno-
reactive for synaptophysin (MacPherson et al. 1997). The
expression of this protein correlates with synapse forma-
tion (MacPherson et al. 1997). Previous studies showed
that reduced synaptic activity causes detrimental effects on
synapses and memory (Tampellini et al. 2010). A
treatment that could restore or preserve synaptic connec-
tions between neurons could be of great potential utility in
treating AD (Bailey and Lahiri 2010). Bailey et al.
demonstrated that rivastigmine treatment in primary
cortical cell culture model cannot only preserve neurons,
but preserve neuronal morphology and synaptic markers
that are vital for normal neuronal function (Bailey and
Lahiri 2010). Also, lithium chloride was reported to
increase mRNA levels of genes encoding synaptophysin
and the 160-kDa neurofilament protein (Schmidt et al.
2001).
In our previous study the presence of nestin, a marker of
neural progenitor cells has been observed in ES cell-derived
neuron induced by selegiline (Esmaeili et al. 2006).
Although this neuroepithelial marker was not directly tested
here, the neuronal population indeed appears stronger in the
selegeline conditions than untreated cultures. Also, positive
staining of β-III tubulin showed differentiation of P19 EC
cells into neurons. The β-III tubulin is a classic marker for
differentiating neurons (Rak et al. 2011). Expression of
brain-specific III tubulin in stem cell-derived neurons has
been shown in previous studies (Falconer et al. 1992;
Kompisch et al. 2010).
Conclusion
Our results documented that the neuronal differentiation of
mouse P19 EC cells, was induced by a neuroprotective
pharmacological drug, selegiline. The differentiated cells
showed a typical neuronal morphology and exhibited a
number of markers characteristic of neurons such as
synaptophysin and β-III tubulin. An understanding of the
molecular mechanism of selegeline may contribute to the
development of new therapies for neurodegenerative dis-
eases. These data suggest that selegiline may have utility in
neurodegenerative diseases due to its effects on synapse
formation.
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